Multiple Myeloma and Other Plasma Cell Neoplasms

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Hematology, Oncology
Cover of the book Multiple Myeloma and Other Plasma Cell Neoplasms by , Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783319255866
Publisher: Springer International Publishing Publication: February 16, 2018
Imprint: Springer Language: English
Author:
ISBN: 9783319255866
Publisher: Springer International Publishing
Publication: February 16, 2018
Imprint: Springer
Language: English

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find *Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management. *

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find *Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management. *

More books from Springer International Publishing

Cover of the book Bone Metastases from Prostate Cancer by
Cover of the book New Perspectives on Surface Passivation: Understanding the Si-Al2O3 Interface by
Cover of the book RNA Metabolism in Mitochondria by
Cover of the book Structural, Syntactic, and Statistical Pattern Recognition by
Cover of the book Polysaccharide-based Fibers and Composites by
Cover of the book Numerical Methods for PDEs by
Cover of the book Structural Nonlinear Dynamics and Diagnosis by
Cover of the book Transformational Sales by
Cover of the book Gastrointestinal Malignancies by
Cover of the book Age of the Geek by
Cover of the book Drug Resistance in Bacteria, Fungi, Malaria, and Cancer by
Cover of the book Manual Small Incision Cataract Surgery by
Cover of the book Coordination Control of Distributed Systems by
Cover of the book Extended Abstracts Fall 2013 by
Cover of the book Non-cooperative Stochastic Differential Game Theory of Generalized Markov Jump Linear Systems by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy